Obesity weight loss injections: separating fact from wishful thinking

The biggest myth: these injections work by suppressing your willpower for you

The most persistent misunderstanding about obesity weight loss injections is that they are a willpower substitute, that you simply inject something and your body does the rest without any change in how you live. That framing misses how the medicines actually function, and it sets people up for disappointment.

Tirzepatide and semaglutide act on receptors in the gut and brain that regulate hunger and satiety. Tirzepatide activates two of those receptor pathways (GIP and GLP-1); semaglutide activates one (GLP-1). Both slow gastric emptying, food moves through your stomach more slowly, so you feel full for longer and naturally eat less. The appetite reduction is biological, not motivational. But that biology works alongside a reduced-calorie diet and increased physical activity, not instead of them. The clinical trials that produced the headline weight-loss figures were all conducted with lifestyle support as a consistent component. If you can read about what a weight loss injection actually involves day to day, that context helps set realistic expectations before you start.

Weight is shaped by biology, genetics, hormones and environment, not by effort alone. These medicines address some of those biological levers. That is different from doing the work for you.

What the licensed injections are, and what the evidence says

There are currently two injectable medicines licensed in the UK specifically for weight management in adults with obesity: Mounjaro (tirzepatide, made by Eli Lilly) and Wegovy (semaglutide, made by Novo Nordisk). Both are given once weekly by a pre-filled pen, injected into the abdomen, thigh or upper arm.

The trial data is substantial. In the SURMOUNT-1 study, involving 2,539 adults with obesity, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks. Semaglutide 2.4mg produced around 15% average weight loss in the STEP 1 trial over 68 weeks. A 2025 head-to-head trial (SURMOUNT-5) found tirzepatide produced greater average weight loss than semaglutide 2.4mg directly compared. These figures come from controlled conditions with consistent lifestyle support, so individual results vary. If you want to compare the options side by side, our overview of the 3 weight loss injections available in the UK sets out how they differ. NICE has appraised both medicines and recommends tirzepatide under TA1026 and semaglutide under TA875 for eligible adults.

Ozempic (also semaglutide) is licensed for type 2 diabetes, not weight management. It is a different product for a different indication, and the two should not be confused.

Who these medicines are licensed for, and the prescription route

Both injections are Prescription-Only Medicines. A prescriber assesses your full clinical picture before treatment is initiated, BMI alone is not sufficient. The licensed eligibility threshold for private treatment is a BMI of 30 or above, or 27 and above if you have at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

On the NHS, access is phased. From June 2025, tirzepatide has been available through GP practices for people with a BMI of 40 or above and four or more qualifying conditions; a second cohort (BMI 35–39.9 with four or more conditions) opened in June 2026. If you want to understand how your GP fits into all of this, our guide to GP-prescribed weight loss injections covers the NHS rollout in detail. Wegovy is available on the NHS through specialist weight management services, though waiting lists are often long. Private treatment through a regulated online pharmacy is an alternative for people who do not currently meet NHS criteria or would rather not wait.

One practical check worth doing before using any online pharmacy: look up its registration on the GPhC pharmacy register. It takes under a minute and confirms the pharmacy is genuine. Fake weight loss pens are a real problem, the MHRA has issued repeated warnings and seized large volumes of counterfeit injectable medicines sold online. If a seller offers these medicines without requiring a prescription and clinical assessment, that is a red flag, not a deal.

Side effects, safety habits, and managing treatment sensibly

The side-effect profile of both injections is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, indigestion and burping are the most commonly reported. These tend to be at their worst in the first week or two after starting or after a dose increase, then settle for most people. Fatigue, headache and dizziness are also reported. Injection-site reactions are possible but uncommon.

More serious but infrequent side effects include acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update highlighting this risk for GLP-1 medicines: if you develop severe stomach pain that spreads to your back, with or without vomiting, seek urgent medical attention. Gallbladder problems and dehydration from prolonged vomiting are also flagged in safety guidance. Any suspected side effect can and should be reported via the Yellow Card scheme.

Pregnancy, breastfeeding and trying to conceive are all situations where these medicines are not recommended. If you use oral contraceptives and start tirzepatide specifically, adding a non-oral method of contraception for the first four weeks and after each dose increase is advised, because the pill's absorption may be reduced. This does not apply in the same way to semaglutide, but the interaction is worth discussing with a prescriber. Fertility considerations have their own nuances, there is more detail on how weight loss injections and fertility interact for anyone planning a pregnancy. These injections are not licensed for use in people under 18.

Thinking about cost is a fair part of the decision. The real cost of weight loss injections is not just the pen price, it includes prescription and clinical oversight, which are necessary rather than optional. A lower headline price that excludes those things is not a saving.

If you'd like your circumstances reviewed by a real clinician rather than reading further, you're welcome to speak to our prescribers through a free consultation.